Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-XPEDITION
- 10 Jul 2017 Planned number of patients changed from 2500 to 4000.
- 15 Jun 2016 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
- 15 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.